IP Library › Granted Patent US 10,358,441
Granted Patent B2
US 10,358,441 · App. 15/898,387 · Granted Jul 23, 2019

Processes for the preparation of benzodiazepine derivatives

Inventors: In Jong Kim (Lexington, MA); Jianming Yu (Plainsboro, NJ); Thomas P. Blaisdell (Brighton, MA); Joseph Panarese (Malden, MA); Brian C. Shook (Holliston, MA); Yat Sun Or (Watertown, MA)
Assignee: Enanta Pharmaceuticals, Inc.
C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,358,441
App. No.
15/898,387
Granted
Jul 23, 2019
Kind
B2
Abstract

The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to processes and intermediates for the preparation of compounds of formula (I): In particular, the present invention also relates to processes and intermediates for the preparation of compound I-a:

Claims (40)

1. A process for preparing a compound of formula (I),

wherein

{circle around (A)} is an optionally substituted aryl or optionally substituted heteroaryl; each n is independently selected from 1 and 2;

m is 0, 1, 2, 3, or 4; and

R 1 is selected from the group consisting of:

1) optionally substituted —C 1 -C 8 alkyl;

2) optionally substituted —C 3 -C 8 cycloalkyl;

3) optionally substituted 3- to 12- membered heterocyclic;

alternatively, two adjacent R 1 groups are taken together with the carbon atoms to which they are attached to form a fused ring; two geminal R 1 groups are taken together with the carbon atom to which they are attached to form a spiro ring; or two R 1 groups on nonadjacent carbon atoms are taken together to form a bridging group;

said process comprising the steps of:

(a) reacting a compound of formula (VII),

wherein R 7 is selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkenyl, 3- to 8- membered heterocyclic, aryl, and heteroaryl; and X is a leaving group;

with a compound of formula (VII-X),

wherein PG is hydrogen or an amine protecting group;

to produce a compound of formula (VIII):

(b) reacting the compound of formula (VIII) with a compound of formula (IX):

to produce a compound of formula (X):

(c) reacting the compound of formula (X) with a compound of formula (III)

wherein R 5 is selected from the group consisting of —O(CO)O—R 6 , optionally substituted aryl, and optionally substituted heteroaryl; and R 6 is selected from the group consisting of optionally substituted C 1 -C 8 alkyl, optionally substituted C 2 -C 8 alkenyl, optionally substituted C 2 -C 8 alkynyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 3 -C 8 cycloalkenyl, optionally substituted 3- to 8 membered heterocyclic, optionally substituted aryl, and optionally substituted heteroaryl;

to produce a compound of formula (V),

 and

(d) reacting the compound of formula (V) with a cyclizing reagent to form the compound of formula (I).

2. The process of claim 1 , wherein

3. The process of claim 1 , wherein step (a) is conducted in a protic solvent at a temperature of about 10° C. to about 70° C.

4. The process of claim 1 , wherein R 7 is hydrogen, and step (a) is conducted in the presence of an amide coupling agent.

5. The process of claim 4 , wherein the amide coupling agent is HATU or EDU.

6. The process of claim 4 , wherein step (a) is conducted in a solvent selected from the group consisting of isopropyl acetate, ethyl acetate, dichloromethane, acetone, THF, NMP, 2-methyltetrahydrofuran, and acetonitrile.

7. The process of claim 1 , wherein R 7 is C 1 -C 8 alkyl, and step (a) is conducted in the presence of protic solvent.

8. The process of claim 7 , wherein the protic solvent is methanol, ethanol, or isopropyl alcohol.

9. The process of claim 8 , wherein step (a) is conducted at a temperature of about 10° C. to about 70° C. for about 3 to 12 hours.

10. The process of claim 1 , wherein step (b) is conducted (i) neat or (ii) in an aprotic solvent; at a temperature about 10° C. to about 100° C.

11. The process of claim 1 further comprising the step of reacting compound (IV),

with a compound of the formula Y—C(O)R 5 , wherein Y is a leaving group, to produce the compound of formula (III).

12. The process of claim 11 , wherein the compound of the formula Y—C(O)R 5 is 1,1′-carbonyldiimidazole or nitrophenyl chloroformate.

13. The process of claim 12 , wherein the compound of formula IV is reacted with the amine activating agent is a solvent selected from the group consisting of acetonitrile, THF, DMSO, and dichloromethane.

14. The process of claim 1 , wherein in step (c) is conducted in acetonitrile, THF, DMSO, DMF, sulfolane or 1-methyl-2-pyrrolidone.

15. The process of claim 14 , wherein step (c) is conducted for 6 to 48 hours at a temperature of about 10 to 50° C.

16. The process of claim 1 , wherein the cyclizing agent of step (d) is para-toluenesulfonyl chloride.

17. The process of claim 16 , wherein step (d) is conducted (i) in the presence of triethylamine or diisopropylethylamine; (ii) in a solvent selected from the group consisting of acetonitrile, THF, DMF, DMSO, NMP, acetone, dichloromethane, ethyl acetate and isopropyl acetate; (iii) at a temperature from about 0° C. to about 30° C., (iv) for about 3 to 15 hours; (v) with a concentration of the compound of formula (III) of about 1 M to 3 M, and (vi) at a ratio of the concentration of the compound of formula (III) and the concentration of the compound of formula (V) of about 1:1.

18. The process of claim 1 , wherein the compound of formula I is compound I-a:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2018
From: KIM, IN JONG; YU, JIANMING; BLAISDELL, THOMAS P.; PANARESE, JOSEPH; SHOOK, BRIAN C.; OR, YAT SUN
To: ENANTA PHARMACEUTICALS, INC.
Reel/Frame 046510/0379 →
Continuity (3)
Provisional Application 62459955 · Feb 16, 2017
Provisional Application 62459953 · Feb 16, 2017
Related Publication 20180237425A1 · Aug 23, 2018
Cited By (5)
US 12,268,694 US 12,297,209 US 12,358,921 US 12,509,470 US 12,612,412